TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Correlation of uraemic toxin concentrations with co-morbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of HIV-positive MSM with new or recurrent AIDS-defining events (clinical stage 4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of HIV-positive MSM died under antiretroviral therapy
Endpoint domain: Mortality/survival
Primary endpoint: Hepatic Iron Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI-derived R2* Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for mechanical ventilation
Endpoint domain: Mortality/survival
Primary endpoint: Esophageal pressure at lung collapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of validated AI device-associated product technical failures (PTFs)
Endpoint domain: Adverse events/effects
Primary endpoint: Shoulder score by Constant and Murley
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of measurement of spirometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change subjective sleepiness (Epworth)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change cognitive impairment by Trail Making Test A & B
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage compliance in completing PE sessions
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Successful Pericardial Access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: T(Max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the General Well-Being Schedule (GWS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Center for Disease Control Health Related Quality of Life-4 (CDC HRQOL-4)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the Quality of Life Enjoyment Scale (Q-LES-Q-SF)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Absolute numbers of CD16+ monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With a Significant Drug-related Adverse Experience
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment response measured by PANSS-a questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe thromboembolic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of total root coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HI titers 4 weeks after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New Knee Society Score (KSS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: full vascularization of the retina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mortality for any cause
Endpoint domain: Mortality/survival
Primary endpoint: Unplanned fracture-related reoperation
Endpoint domain: Adverse events/effects
Primary endpoint: Post-procedure surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of re-tear at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Generalized Anxiety Disorder scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Emotion visual analog scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of osteotomy gap volume filled with bone healing tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: AUS Removal/Revision
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Vaccines Administered
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adequate preoxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in the intensity of bladder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower extremity muscle power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of activin and inhibin A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: postoperative level of ACTH hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Perineal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteogenic potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of detectable platelet proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Progression-free-survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in internalizing and externalizing symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in trauma symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Post-illumination pupil response (PIPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Objective sleep quality: actigraphy
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change from Subjective sleep quality: PSQI
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Reduction in phosphorylation of EGFR, AKT, and ERK
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Gingival index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: biopsy documented rejection episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Resumption of walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of intracyclic bleeding and/or spotting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Risk of Cerebrovascular Events
Endpoint domain: Mortality/survival
Primary endpoint: level of IFN-y secretion in whole blood or PBMC fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Degree of pelvic posterior tilt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Who Experienced Dose-Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients in Non-progression at 6 Months (RECIST V1.1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pain relief in extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Complete Effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local progression free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Sulforaphane Bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiovascular effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of mRS (0-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Screened With a Validated Tool
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants That Receive Services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Diagnosis of Diabetes at 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response to androgen deprivation therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to the last quantifiable time point (AUC(0-t))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to infinity (AUC(0-∞))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration at 24h post-dose (C24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in dietary habits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lifestyle activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Number of ADE Reporting
Endpoint domain: Adverse events/effects
Primary endpoint: ISTH major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the Healthy Snacking Index
Endpoint domain: Life impact
Endpoint subdomain: Nutrition
Primary endpoint: Change in FKBP51 gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Skin responses
Endpoint domain: Adverse events/effects
Primary endpoint: Impact of 18F-DCFPyL PET/CT on treatment strategies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement with preexisting beliefs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Disagreement with preexisting beliefs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of glucose appearance after meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Sustained Abstinence in Substance Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Behavior during initial dental exam
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Behavior during recall exam
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Retrieval rate of clipped node and Magseed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Plasma expression of Interleukin-6 (IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Average Number of Spontaneous Bowel Movements (SBMs) Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cancer pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cancer pain quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: biomarkers for hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: biomarkers for hyperinsulinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: biomarkers for inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Successful Reduction of Radial Head Subluxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Hamilton Depression Rating Scale-17 item (HDRS-17)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in QIDS-16-SR (Quick Inventory of Depressive Symptomatology-16 Self Report)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Visual Analog Scale-Depression (VAS-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pressure Pain Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Paraspinal Asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Response rate (preoperative response rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety (rate of perioperative safety findings)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in symptoms of dry eye: Ocular Surface Disease Index (OSDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in tear film osmolarity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in tear film break-up time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in zinc and selenium plasmatic levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Carotid plaque inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Point prevalence smoking cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composition of monocyte subpopulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Comparison of NIBP values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Comparison of temperature values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison of SpO2 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Comparison of respiration values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Comparison of ECG values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Developmental Level
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in mean peak WAT-1 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration (Cmax) in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum observed concentration (tmax) in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from hour 0 to the last measurable concentration (AUC0-last) in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scar revision effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in biomarker panel measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MRS/MRI scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Potentially Related to Presence of Particle Load in the GLASSIA Solution
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Reactions (ARs) Plus Suspected Adverse Reactions (ARs) Within 24 Hours Following the End of IP Infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Reactions (ARs) Plus Suspected Adverse Reactions (ARs) Within 72 Hours Following the End of IP Infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of cases with > 5 cm with tru-cut biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of biopsies carried out by sarcoma teams vs not sarcoma team
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of patients with image studies at diagnosis and before surgery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of patients discussed in Multidisciplinary Team before treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of patients with specified histopathological grade in pathologic report
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction of hypoglycemia unawareness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of micro-circulatory function from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With HIV-1 RNA < 50 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Walking Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of iodine mapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal Nerve Fibre Layer Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Optic Nerve Head Topography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cup/Disc Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: QLQ-C30 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hamilton Rating Scale for depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Risk of PTSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with treatment-emergent adverse events, categorized by severity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of symptomatic urinary tract infections per patient per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Drug Discrimination Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of aggressive behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent reduction in quantitative HBV DNA levels at 2 weeks post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percent reduction in quantitative HBV DNA levels at 4 weeks post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: physician engagement
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: time for local or provincial research ethics approval
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: accrual rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: patient/physician compliance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient transition satisfaction (Pre)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient transition satisfaction (Post)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Whole-mouth Mean Bleeding Index (BI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unbound Cefazolin Concentration in Skeletal Muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Unbound Cefazolin Concentration in Adipose Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Level of Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Symptomatic thromboembolic events (DVT, PE)
Endpoint domain: Adverse events/effects
Primary endpoint: Prostaglandin E2 metabolite (PGE-M) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of FFP104
Endpoint domain: Adverse events/effects
Primary endpoint: Urine spectral profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Decayed, missing and filled teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRT Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Without NG4 Pulse Generator Related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in inflammatory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Morbidity episodes
Endpoint domain: Adverse events/effects
Primary endpoint: change in total body fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Volume of hLZ consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bispectral Index Score (BIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of guidelines in detecting COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of nonalcoholic fatty liver disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Maximum Concentration (Cmax) of IMC-CS4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Concentration (Cmin) of IMC-CS4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of IMC-CS4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Clinician experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hepatitis B antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes